



MEDESIS PHARMA: OUTCOME OF THE MONTPELLIER COMMERCIAL COURT RULING IN THE LEGAL DISPUTE BETWEEN MEDESIS PHARMA AND BPI FRANCE

Montpellier, June 8, 2023 at 8:00 a.m. — MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary technology for the administration of active pharmaceutical ingredients in nanomicelles by the buccal route, Aonys®, announces the receipt of the judgment by the Montpellier Commercial Court in the legal dispute that has opposed it to BPI France since 2014. All the claims made by BPI France, the initiator, have been deemed admissible and well-founded, and Medesis Pharma has been dismissed of its claims and ordered to pay €1.4 million in respect of the four financing contracts from 2008 to 2010. The amounts provisioned in the accounts since 2020 cover BPI France's claims.

Following receipt of this unacceptable ruling, a repayment plan adapted to the company's cash-flow reality has just been proposed to BPI France's management.

About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood—brain barrier (BBB).

This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and resistant cancers.

Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.

French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 12 patent families and 72 patents, the result of 20 years of research.

Medesis Pharma shares are listed on Euronext Growth Paris: FR001844464 - ALMDP

For more information:

www.medesispharma.com

MEDESIS PHARMA

Jean Claude Maurel Tel: +33 4 67 03 03 96 contact@medesispharma.com

CALYPTUS

Marie Calleux Tel: +33 1 53 65 68 66 medesispharma@calyptus.net

MEDESIS PHARMA 1